NewsClostridioides difficile infectionJun 2, 2026
Idorsia's C. difficile Vaccine Shows Continued Positive Clinical Progress
Idorsia's investigational vaccine, IDOR-1134-2831, targeting Clostridioides difficile infection (C. diff), has demonstrated continued positive clinical trajectory in early-stage trials. The vaccine aims to prevent recurrent C. diff infections, a significant unmet medical need.
Dr. Elena Rossi
